Add-on effects of Chinese herbal medicine external application (FZHFZY) to topical urea for mild-to-moderate psoriasis vulgaris: Protocol for a double-blinded randomized controlled pilot trial embedded with a qualitative study

PLoS One. 2024 Mar 21;19(3):e0297834. doi: 10.1371/journal.pone.0297834. eCollection 2024.

Abstract

Psoriasis vulgaris is a chronic dermatological disease with a high global prevalence. It significantly reduces patients' quality of life and is associated with a substantial economic burden. Conventional therapies for mild-to-moderate psoriasis are often associated with insufficient long-term symptomatic relief and side effects. Chinese herbal medicine (CHM) is commonly used for psoriasis management. A CHM formula, namely Fu zheng he fu zhi yang (FZHFZY), has shown promising treatment effects in clinical practice when used as a bath therapy. However, its efficacy and safety has not been evaluated by a rigorous randomized controlled trial (RCT). Therefore, we designed a double-blinded pilot RCT embedded with a qualitative study on CHM formula FZHFZY plus topical urea for mild-to-moderate psoriasis vulgaris to advance the evidence development and practice of CHM external application for psoriasis. This will be a mixed-method design consisting of a pilot RCT and a qualitative study. The pilot RCT is a two-arm, parallel, placebo-controlled, double-blinded trial. Sixty eligible participants will be randomized at a 1:1 ratio to receive eight weeks' treatment of either FZHFZY plus 10% urea cream, or placebo plus 10% urea cream, with 12-week follow-up visits after the treatment phase. The CHM or placebo will be administered externally as a bath therapy. Outcome measures include trial feasibility, efficacy and safety. The primary efficacy outcome will be Psoriasis Area Severity Index (PASI). Secondary efficacy outcomes include Physician Global Assessment, PASI-75, PASI-50, Body Surface Area, Dermatology Life Quality Index, Skindex-16, itch visual analogue scale and relapse. The qualitative study will be conducted to collect participants' feedback on CHM external application and their experience with the pilot RCT. This study will advance the evidence-based clinical practice of using CHM for psoriasis vulgaris and then to support translation of findings into clinical practice in the future. Trial registration number: ChiCTR2200064092.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Double-Blind Method
  • Drugs, Chinese Herbal* / adverse effects
  • Humans
  • Neoplasm Recurrence, Local
  • Pilot Projects
  • Psoriasis* / drug therapy
  • Randomized Controlled Trials as Topic
  • Severity of Illness Index
  • Treatment Outcome
  • Urea / therapeutic use

Substances

  • Drugs, Chinese Herbal
  • Urea

Grants and funding

This trial is a part of funded projects ‘2022 TCM Innovation Team and Talent Support Program of the State Administration of Traditional Chinese Medicine (No: ZYYCXTD-C-202204)’, ‘the Guangzhou Science and Technology Planning Project (No.202206080006)’, ‘Clinical Medicine Research Centre in Guangdong Province, Department of Science and Technology of Guangdong Province (No. 2020B1111170012)’, ‘Specific Research Fund for Chinese Medicine Science and Technology, Guangdong Provincial Hospital of Chinese Medicine’ (No. YN2019QL11) and supported by the Guangdong Provincial Academy of Chinese Medical Sciences, China, and RMIT University, Australia, through the China–Australia International Research Centre for Chinese Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.